Patient Resources

Trabectedin or Dacarbazine for the Treatment of Patients with Advanced Liposarcoma or Leiomyosarcoma

Janssen Research & Development, L.L.C. is conducting a Phase 3 clinical trial for trabectedin or dacarbazine in patients with liposarcoma or leiomyosarcoma. This is a randomized (study drug assigned by chance), open-label (all patients and study staff know the identity of the assigned study drug), active-controlled (comparing to a different drug used for the same condition), parallel-group (different treatment groups continue with separate treatments throughout the study), multicenter study. This study will be divided into three phases, screening, treatment, and follow-up. During screening, potential patients will be assessed for study eligibility after providing signed informed consent. During the treatment phase, patients will receive study drug once every 3 weeks, until disease progression or signs of toxicity. Assessments will be performed to evaluate the effectiveness of the drug, and patient safety will be monitored. During the follow-up phase, after the last dose of study drug, clinical outcomes for patients will be evaluated. Trabectedin will be administered at a dose of 1.5 mg/m2 through a catheter into a large vein as a 24-hour intravenous (IV) infusion, once every 3 weeks, until disease progression or signs of toxicity. Dacarbazine will be administered at a dose of 1.0 g/m2 as a 20 to 120-minute infusion, once every 3 weeks, until disease progression or signs of toxicity. For more information on this study, please visit http://www.l-sarcomastudy.com or http://www.clinicaltrials.gov (Identifier # NCT01343277).

Programs & Resources

Patient Resources

Information on sarcoma subtypes, treatments, clinical trials, and other important resources for sarcoma patients and families.

Sarcoma Patient Registry

Information on the Sarcoma Patient Registry. If you are diagnosed with sarcoma, please consider joining the Registry.

Research Grants

Information on applying for a sarcoma research grant, current research funded by the SFA, and past research grants.